Tsakonas G, et al. - Researchers examined the link between c-MET H-score and overall survival (OS) as well as progression-free survival in 725 patients with surgically removed non-small cell lung cancer (NSCLC) included in this retrospective cohort study. In tissue microarrays from lung tumors and healthy tissue, immunohistochemistry (IHC) was performed. Using H-scores (range 0-300), they quantified IHC staining. According to findings, c-MET H-score ≥20 was identified as a positive prognostic biomarker for OS in early stage NSCLC. A strong correlation of this benefit to adjuvant chemotherapy was suggested, which was indicative of a possible significance of c-MET H-score ≥20 as a predictive biomarker for platinum-based adjuvant chemotherapy in early stage NSCLC.